MedTrace Logo

The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes

NCT04219124 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2021-04-27

No results posted yet for this study

Summary

The study is a randomised double blind placebo control cross over trial with 4 weeks washout period. The expected duration of participant participation is 103 days. the study aims to investigate the effect of dapagliflozin, a SGLT2 inhibitor, on glucose flux, lipolysis and exercise in patients with type 2 diabetes.

Conditions

Interventions

DRUG

IMP oral tablet

Dapagliflozin 10 MG

DRUG

Placebo oral tablet

Matching placebo tablets

Sponsors & Collaborators

  • Royal Surrey County Hospital NHS Foundation Trust

    collaborator OTHER

  • AstraZeneca

    collaborator INDUSTRY

  • University of Leicester

    lead OTHER

Principal Investigators

  • Roselle Herring, MD PhD · CEDAR, Royal Surrey County Hospital

  • Mellanie Davis, MD PhD · University of Leicester

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-20
Primary Completion
2020-01-08
Completion
2020-01-08

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04219124 on ClinicalTrials.gov